Our study revealed that JFK deficiency sensitizes breast cancer cells to chemo-radiotherapeutic treatment under hypoxia, indicating that hypoxia-induced JFK upregulation in basal-like tumors might contribute to drug resistance. This evidence concerns the gene FBXO42 and breast cancer.